Simian Acquired Immunodeficiency Syndrome

Acquired defect of cellular immunity that occurs naturally in macaques infected with SRV serotypes, experimentally in monkeys inoculated with SRV or MASON-PFIZER MONKEY VIRUS; (MPMV), or in monkeys infected with SIMIAN IMMUNODEFICIENCY VIRUS.

Also Known As:

Networked: 93 relevant articles (4 outcomes, 12 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Amyloidosis
2.	Simian Acquired Immunodeficiency Syndrome
3.	Acquired Immunodeficiency Syndrome (AIDS)
4.	Infection
5.	Opportunistic Infections (Opportunistic Infection)

Experts

1.	Lewis, Mark G: 3 articles (01/2013 - 01/2008)
2.	McClure, Harold M: 3 articles (01/2008 - 02/2004)
3.	Suzuki, Shunji: 3 articles (01/2005 - 06/2002)
4.	Chuang, Ronald Y: 3 articles (01/2005 - 06/2002)
5.	Doi, Roy H: 3 articles (01/2005 - 06/2002)
6.	Chuang, Linda F: 3 articles (01/2005 - 06/2002)
7.	Garaci, Enrico: 2 articles (01/2013 - 01/2010)
8.	Chirullo, Barbara: 2 articles (01/2013 - 01/2010)
9.	Savarino, Andrea: 2 articles (01/2013 - 01/2010)
10.	Paiardini, Mirko: 2 articles (12/2005 - 02/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Simian Acquired Immunodeficiency Syndrome:

1.	VaccinesIBA 09/01/2007 - "All HIV vaccine strategies tested in neonatal macaques are immunogenic, but only a subset of these vaccines confer significant protection against virus acquisition or simian AIDS after oral challenge. " 08/01/2007 - "A subsequent study will evaluate the ability of rSVV vaccines expressing SIV antigens to protect nonhuman primates against simian AIDS."
2.	InterleukinsIBA 11/01/2015 - "Interleukin (IL)-6 blockade is frequently effective in inflammatory conditions, however, there are few published data on its use in AA amyloidosis or the systemic autoinflammatory diseases (SAIDs) or chronic inflammatory conditions. "
3.	MK 0518FDA Link 01/01/2010 - "Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy."
4.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 07/01/2011 - "Our in vitro study indicates that steroidal anti-inflammatory drugs (SAIDs) as well as nonsteroidal anti-inflammatory drugs (NSAIDs) have immunosuppressive effects on calf PBMCs. " 01/01/2015 - "During the first postoperative year complete success of the treatment was achieved in 50% of the controls, 65% of the NSAIDs patients, 75% of the SAIDs patients, and 80% of those under combination therapy. " 01/01/2015 - "Further hypotensive therapy was required in 50% of the control group, 35% of the NSAIDs group, 25% of the SAIDs group and 20% of the combination-therapy group. " 01/01/2015 - "Postoperative needling was required in 50% of the controls, 35% of the NSAIDs and 30% of the SAIDs patients as well as 20% the combination-therapy patients. " 01/01/2013 - "Pharmacological validation of this optimized assay was performed with a panel of anti-inflammatory drugs, demonstrating a concentration-responsive inhibition of leukocyte migration for both steroidal and non-steroidal anti-inflammatory drugs (SAIDs and NSAIDs). "
5.	Interleukin-7 (Interleukin 7)IBA 02/01/2004 - "In 5 macaques that progressed to simian AIDS and death, elevated IL-7 levels were unable to restore T-cell homeostasis. " 12/01/2005 - "These data contrast with our earlier studies in SIVmac-infected macaques, in which the IL-7 increase was delayed until 20 to 40 weeks after infection, just before the onset of simian AIDS. " 02/01/2004 - "Further, studies in sooty mangabeys that do not progress to simian AIDS and that maintain stable T-cell numbers despite high levels of viral replication support the importance of IL-7 and T-cell homeostasis in disease progression. "
6.	AntigensIBA 11/01/1989 - "A rapid, sensitive and specific antigen capture (AC) assay has been established for the detection of p27 core protein of SAIDS type-D retrovirus (SRV). " 11/01/1989 - "The relatedness of PMFV to further type D retroviruses (Mason-Pfizer monkey virus, MPMV; SAIDS retrovirus type 2, SRV-2) was also demonstrated by cross-hybridization of cloned DNAs under different stringencies (i) using full-length genomic probes of PMFV, MPMV, and SRV-2 and (ii) by DNA sequence analysis of regions of the group specific antigen (gag) protease (prt), polymerase (pol), and envelope (env) genes." 07/18/1986 - "The envelope antigen of the West African virus can be recognized by serum from a macaque with simian AIDS infected by the simian retrovirus termed STLV-IIImac, suggesting that the West African AIDS virus may be more closely related to this simian virus than to LAV. " 07/01/1985 - "Although the antigens of the three prototype AIDS viruses were similar, no cross-reactivity with the SAIDS virus was detected. " 08/01/2007 - "A subsequent study will evaluate the ability of rSVV vaccines expressing SIV antigens to protect nonhuman primates against simian AIDS."
7.	DNA (Deoxyribonucleic Acid)IBA 04/20/1984 - "Nucleic acid hybridization studies reveal that the origin of the SAIDS-D isolate may reside in Old World monkey (subfamily Colobinae) cellular DNA." 04/25/2006 - "DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued." 08/01/2002 - "In contrast, animals that were inoculated with SIV at 11 weeks after RhCMV infection rarely exhibited RhCMV DNA in plasma, had low copy numbers of RhCMV DNA in most tissues, and did not develop early onset of SAIDS or activated RhCMV. " 07/01/1989 - "SRV-1 DNA and RNA have previously been detected in the brains of rhesus monkeys with SAIDS in the absence of viral antigen or neuropathological lesions. "
8.	Interleukin-6 (Interleukin 6)IBA 01/01/2007 - "Results confirmed the sensitivity of LCL8664, an immunoblastic SAIDS-NHL cell line, to TGF-beta1-mediated growth inhibition, and further demonstrated the partial rescue by simultaneous treatment with IL-6. " 01/01/2007 - "These studies indicate that the sensitivity of immunoblastic AIDS- or SAIDS-DLBCL to TGF-beta1-mediated growth inhibition may be overcome through the stimulation of proliferative and anti-apoptotic signals by IL-6, particularly through the rapid activation of STAT3." 06/01/1991 - "Interleukin-6 and retroperitoneal fibromatosis from SRV-2-infected macaques with simian AIDS." 01/01/2007 - "The present study was conducted to assess whether other SAIDS-NHL and AIDS-NHL cell lines are similarly sensitive to the growth inhibitory effects of TGF-beta, and to test the hypothesis that interleukin-6 (IL-6) may represent a counteracting positive influence in their growth regulation. " 06/01/2001 - "Steroidal anti-inflammatory drugs (SAIDs) exhibited significant inhibitory effects at 100 microM on the IL-6 bioactivity, and their inhibitory potencies were in the order of budesonide (IC50=2.2 microM)>hydrocortisone 21-hemisuccinate (6.7 microM), prednisolone (7.5 microM), betamethasone (10.9 microM)>dexamethasone (18.9 microM) and triamcinolone acetonide (24.1 microM). "
9.	Quinolinic AcidIBA 06/01/1990 - "In the present study, inoculation of macaques with D/1/California, an immunosuppressive serotype 1 type D retrovirus, was associated with acute and chronic increases in CSF and serum quinolinic acid concentrations in macaques that had developed SAIDS, a simian disease analogous to AIDS in humans--particularly macaques with demonstrable opportunistic infections. " 06/01/1990 - "CSF quinolinic acid, but not kynurenic acid, was also increased in viremic macaques with SAIDS-related complex (2.4-fold) and asymptomatic virus positive carriers (3.4-fold). " 07/01/1997 - "Quinolinic acid and lymphocyte subsets in the intrathecal compartment as biomarkers of SIV infection and simian AIDS." 06/01/1990 - "Kynurenic acid, an antagonist of excitatory amino acid receptors as well as the excitotoxic effects of quinolinic acid, was also increased in the CSF of SAIDS macaques, but to a significantly lesser degree than was quinolinic acid (kynurenic acid, 1.8-fold; quinolinic acid, 15.6-fold). "
10.	KynurenineIBA 02/01/1991 - "In the present study, increased activity of indoleamine-2,3-dioxygenase (IDO), the first enzyme of the kynurenine pathway, occurred in cerebral cortex and lung of macaques with clinical SAIDS. " 06/01/1990 - "Increased activity of indoleamine-2,3-dioxygenase, the first enzyme of the kynurenine pathway, was indicated in the macaques with SAIDS by reduced serum L-tryptophan and elevated serum L-kynurenine concentrations. "

Therapies and Procedures

1.	Investigational Therapies (Experimental Therapy) 01/01/2013 - "Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS."
2.	Immunomodulation 01/01/2012 - "Successful treatment response to nonsteroidal anti-inflammatory drugs (NSAIDs), steroidal anti-inflammatory drugs (SAIDs), immunosuppressive therapy drugs (immunomodulatory therapy [IMT]), or biologic response modifiers (BRMs) was assessed. "
3.	Trabeculectomy (Trabeculoplasty) 01/01/2015 - "To assess potential of preoperative therapy with local steroid and non-steroid anti-inflammatory drugs (SAIDs and NSAIDs) for prolonging the hypotensive effect of trabeculectomy. "
4.	Intravenous Infusions 11/01/1989 - "Ten macaques naturally infected with simian acquired immunodeficiency syndrome retrovirus serotype 2 (SRV-2), the etiologic agent of simian acquired immunodeficiency syndrome, received ddC by continuous intravenous infusion or by a daily bolus injection for 10 to 12 days. "
5.	Drug Therapy (Chemotherapy) 04/25/2006 - "DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued."